Bayer price target lowered to EUR 68 from EUR 82 at Morgan Stanley » 11:4210/2110/21/20
Morgan Stanley analyst…
Story temporarily locked.
Abbott sees COVID-19 testing as a 'growth driver' 09:5510/2110/21/20
Abbott says seeing 'signs of recovery' in areas hit hardest from COVID-19 » 09:3710/2110/21/20
Says expects momentum to…
Says expects momentum to carry into 2021. Expects COVID-19 testing to be "big boost" for the company. Expects demand for COVID-19 tests to remain high through 2021. Says generating "nice cash," and does not see any change to capital allocation strategy. Says FreeStyle Libre is a "platform" for mass-market penetration and there will be continued innovation in products. Comments taken from Q3 earnings conference call.
Abbott sees double-digit sales, EPS growth in Q4 » 09:1510/2110/21/20
Q4 EPS/revenue consensus…
Q4 EPS/revenue consensus $1.21/$9.6B, respectively
PTC Therapeutics: Evrysdi approved in Brazil for treatment of SMA » 08:3510/2110/21/20
PTC Therapeutics (PTCT)…
PTC Therapeutics (PTCT) tannounced that Evrysdi was approved in Brazil by the National Health Surveillance Agency for the treatment of spinal muscular atrophy. The approval was obtained within seven months of Roche's (RHHBY) initial submission and marks the second country to approve Evrysdi. Additionally, PTC announced the filing of a New Drug Application for Evrysdi for the treatment of SMA with the Japanese Ministry of Health, Labor and Welfare. The filing in Japan by Chugai Pharmaceutical Co. Ltd., a member of the Roche group, triggers a $7.5M milestone payment to PTC from Roche.
Eli Lilly hires advisor to review plant producing C-19 treatment, CNBC reports » 08:2610/2110/21/20
Eli Lilly has hired an…
Abbott CEO says 'new product pipeline continues to be highly productive' » 07:3710/2110/21/20
"Our strong results…
"Our strong results and increased guidance are a direct reflection of our ability to innovate and deliver despite challenging conditions," said Robert Ford, president and CEO, Abbott. "Our new product pipeline continues to be highly productive, and we're well-positioned to finish the year with a lot of momentum."
Abbott reports Q3 FreeStyle Libre growth of 37.9% on reported basis » 07:3510/2110/21/20
In Diabetes Care, strong…
Abbott reports Q3 Worldwide Medical Devices sales up 3.4% on reported basis » 07:3210/2110/21/20
Worldwide Medical Devices…
Abbott raises FY20 adjusted EPS view to 'at least' $3.55 from 'at least' $3.25 07:3110/2110/21/20
FY20 consensus $3.32.